Spain’s Rovi acquires Hexal anticoagulant for German marketSpain’s Rovi has paid Hexal €9 million to market anticoagulant Falithrom (phenprocoumon) in Germany, daily La Vanguardia, financial Cinco Días and medical journal Diario Médico reported on Wednesday.
CHMP disregards omega-3 fatty acid medicines in cardiac preventionThe European Union will no longer authorise medicines based on omega-3 fatty acids to prevent further cardiac events in patients with a previous myocardial infarction, daily ABC, Europa Press agency and a number of regional newspapers reported on Thursday and Friday. (APMHE 61086)
AstraZeneca hires controversial Spanish oncologistJosé Baselga, who resigned from his position as chief medical officer at Memorial Sloan Kettering Cancer Center in New York after The New York Times exposed his failure to disclose payments from pharma in various research papers, has been hired by AstraZeneca to lead its R&D unit, it was widely reported on Tuesday. (APMHE 61326)
Lilly acquires Loxo in €7 billion dealEli Lilly has announced an agreement to acquire U.S. firm Loxo Oncology in a $8 billion (€6.9 billion) deal, daily El Periódico, financials Cinco Días, Expansión, Europa Press agency, medical journals Diario Médico and Redacción Médica reported on Monday. (APMHE 61318)
EMA recommended 42 new drugs in 2018The European Medicines Agency (EMA) recommended 42 new active substances for marketing authorisation in 2018, a 20% increase from the previous year, financial El Economista, Europa Press agency, medical journals Diario Médico, El Médico Interactivo, IM Médico Hospitalario reported on Thursday. (APMHE 61303)
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.